Clinical Trial Update: FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating FLT3 ligand and CD40 agonist antibody with stereotactic radiotherapy for lung cancer (non-small cell/non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• CD40 agonist antibody (CD40 agonist antibody)
• FLT3 ligand (FLT3 ligand)

Snippet

Sponsor: Albert Einstein College of Medicine | Conditions: Non Small Cell Lung Cancer, Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-07-17